• The Green Organic Dutchman has applied for listing of its common shares on the Nasdaq
• The company announced quarterly and half-yearly financial and operational results for the periods ended June 30, 2019
• Progress of its construction efforts at two sites was included on a list of corporate highlights

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) recently announced that it has applied for a listing of its common shares on the Nasdaq. The listing will require numerous regulatory moves on the part of the company, including registration of the common shares and a confirmation by the Nasdaq that TGOD has met all applicable listing requirements.

“This is an important step in the growth of TGOD, one that will broaden our investor base and increase access for international investors as we build the leading global organic cannabis brand,” TGOD CEO Brian Athaide stated in a news release (http://ibn.fm/JX1Ky). “Our team remains focused on executing our business plan and creating value for our shareholders.”

In addition to its Nasdaq application, TGOD announced its financial and operational results for the period ended June 30, 2019 (http://ibn.fm/9IIRc). “Q2 was pivotal for the company as we began commercial production in the second phase of our Hamilton site and expanded our product line for the Grower’s Circle,” Athaide continued.

Highlights of the company’s operations and performance during the quarter included the following:

• Construction of the company’s Hamilton site and phase 1 at its Valleyfield site are nearing completion. The investment value reached $53.1 million in the second quarter of 2019, with total investments for the year amounting to $100.9 million.
• TGOD achieved a revenue increase of 20 percent over the prior quarter, with revenues amounting to $2.9 million and stemming primarily from the European markets. The company reported a net loss of $16.6 million for Q2 2019 but continues to maintain fiscally responsible practices.
• The company launched its Grower’s Circle project in Canada, which is currently testing the company’s sales and distribution capabilities.

Athaide commented on his team’s commitment to executing its “ambitious” business plan, realizing double digit quarterly growth in Europe and nearing the end of its construction project in Canada. “The product quality feedback from Grower’s Circle has been overwhelmingly positive, confirming that patients appreciate having access to premium certified organic cannabis, an underserved segment of the market,” Athaide added (http://ibn.fm/rjzBY). “We now have our first purchase order from the OCS in hand and look forward to shipping our first recreational sales this week.”

The Green Organic Dutchman produces organic, pesticide-free cannabis using crafting techniques in farming. The company envisions becoming a global leader in providing premium-quality cannabis products that improve the lives of its customers. The company currently conducts operations in the medical cannabis markets of Canada, Europe, the Caribbean and Latin America.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

• ETST outlined a multiple-year goal of growing a market for its pure, natural extracted products in the CBD space
• The company creates proprietary CBD products that are unique to the nutraceuticals industry
• Its cutting-edge technology, including its super-critical extraction process, is designed to create pure and natural hemp oil

Earth Science Tech Inc. (OTCQB: ETST) outlined a five-year plan in its July 10-K annual report filed with the SEC. The report details a strategy of creating ETST’s proprietary line of CBD hemp extracts through a gentle and natural process that utilizes a super-critical extraction process using CO2 compression, isolation and micron filtration (http://ibn.fm/H330b).

The result is high-grade, CBD-rich hemp oil and other CBD products that have additional natural molecules. ETST’s highly technical extraction process creates pure, easily digested, rich CBD hemp oil that’s unique to the nutraceuticals industry. ETST plans to scale-up its processing capability to accommodate new products in its pipeline, per the report, and it aims to make its innovative hemp products available worldwide.

The report also explained that hemp-based CBD is one of at least 80 cannabinoids found in hemp and is non-psychoactive.

ETST’s U.S.-based operation oversees its supply chain, including raw material processing, product development and manufacturing, and sales and marketing. ETST plans to continue expanding its line of supplements and proprietary CBD-rich hemp oil to broad and diverse channels, including online, pharmacies, clinics and in-store sales.

ETST is currently sourcing its CBD-rich hemp oil from high-quality industrial hemp plants grown in Oregon and Kentucky. Referencing its product’s cultivation, ETST maintains that its CBD-rich hemp oil is “sourced from the high quality industrial hemp plants grown by generational family farmers,” and that, throughout the process, the product is lab tested several times “from seed to shelf” for “cannabinoid panel content, terpenoids, pesticides, residual solvents, mycotoxins and micros.” This attention to detail in production quality is a valuable hallmark of ETST’s success, differentiating it from its competitors.

“We believe that our formulations will set us apart from competing products for promoting health,” the company stated in the SEC filing. “We have formulated and produced our initial CBD products, intended for subject to performance treating various symptoms of diseases and ailments or for overall health. The company plans to expand manufacturing and marketing of these CBD products with expansion of products over the next five years.”

ETST is a biotech company focused on the nutraceutical and pharmaceutical fields. It performs R&D on cannabis and industrial hemp, markets a line of cannabis products, and maintains a portfolio of diverse subsidiaries.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

• Petroteq Energy’s proprietary Clean Oil Recovery Technology (CORT) can extract up to 99 percent of crude oil and produces no waste or greenhouse emissions
• CORT licensing is seen as a future line of growth for Petroteq
• The company announced that it has received positive lab results regarding the recovery of oil from international ore samples
• The company recently sealed a major licensing agreement with Texas energy company Valkor

Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) is revolutionizing the heavy oil recovery process through its clean, closed-loop technology that’s capable of extracting fuel from sands and returning the cleaned sands back to the earth.

The proprietary mechanism is called Clean Oil Recovery Technology (CORT). The technology was developed for surface tar-sand extraction, and it is suitable for all hydrocarbon deposits. The patented 14-stage process can extract up to 99 percent of crude oil and recycle over 99 percent of the solvent used in the process. CORT can also be deployed for land remediation projects, either independently or integrated with other processes.

Several key advantages define the superiority of the CORT approach. The technology does not require any water; it does not emit greenhouse gas; and it does not require high temperatures. Additionally, the process leaves virtually no waste; the only product returned back after the completion of the extraction is clean sand.

An August 19, 2019, press release announced that the company has received positive lab results on the recovery of oil from international ore samples. Stage 1 laboratory testing with the oil sands samples provided by a separate Asian energy firm using Petroteq’s CORT on oil sands samples was completed on August 15, 2019. The testing was undertaken to determine the geophysical characteristics of the oil and demonstrated that Petroteq’s proprietary technology was able to recover a maximum oil content of approximately 20 percent saturation, with results approaching greater than 90 percent yield of heavy oil from the supplied surface minable heavy oil project samples.

In addition, Petroteq reported results from its stage 2 laboratory testing with oil shale samples provided by Queensland Energy Mining Limited (“QEM”) using Petroteq’s CORT on previously drilled QEM core samples. The preliminary stage 2 QEM test results demonstrated that Petroteq’s proprietary technology was able to recover up to 65 percent of the contained oil from Julia Creek project samples.

Petroteq is making the technology available to other organizations in the field, as well. On July 2, 2019, the company announced its entry into a non-exclusive technology licensing agreement with Valkor LLC, an eastern Texas energy services company (http://ibn.fm/re0Zh). This licensing agreement for Petroteq’s CORT grants Valkor non-exclusive rights to the use of the patented extraction solution.

This is the first licensing agreement that demonstrates the potential of CORT. Petroteq currently envisions opportunities to license the extraction technology in more than 20 countries that have oil sand resources.

CORT roll-out discussions are ongoing in parts of the world like Canada, the Middle East, Africa and South America. The proprietary nature of the technology, its enhanced extraction capabilities and its remediation opportunities give Petroteq significant growth potential upon which it intends to capitalize in the future.

“The licensing model is an important component of the Petroteq business model allowing Petroteq to leverage its proprietary technologies and operating techniques to participate in value created through investment by other companies and strategic investors,” an official corporate announcement reads.

According to Valkor CEO Steve Byle, prior cooperation with Petroteq shows that the CORT platform is unique and highly effective. It is a great match to Valkor’s long-term strategy, Byle concluded in a news release.

Petroteq Energy is a Canadian-registered publicly traded company that focuses on the development and implementation of proprietary solutions for the sustainable extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits.

The company has currently concentrated its oil sand exploration and production efforts on Utah and, more specifically, its Asphalt Ridge project. The Asphalt Ridge mineral lease spans 2,500-plus acres and features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent.

For more information, visit the company’s website at www.Petroteq.energy

NOTE TO INVESTORS: The latest news and updates relating to PQEFF are available in the company’s newsroom at http://ibn.fm/PQEFF

• SING president reports that the company’s solar division is growing in residential markets and expanding into commercial markets
• In the industrial hemp and CBD sector, SING is debuting a lotion product, expanding TorusMed and adding a water-soluble tincture product
• SING was named as the master distributor for the Pure Hemp line of American-grown hemp cigarettes

SinglePoint Inc. (OTCQB: SING) President Wil Ralston said on MoneyTV that SING is growing in several directions. During an interview with host Donald Baillargeon (http://ibn.fm/K0SZW), Ralston projected that the company’s solar division will generate some $5 million in revenues this year as it continues to increase residential sales and adds commercial sales while also providing funding options for small to medium businesses on renewable projects.

During the interview, Ralston predicted that, for SING’s year ended December 31, 2019, solar would generate an estimated $5 million in revenues. “There’s just so much going on in the renewables space that we’re able to tap into, especially through the Direct Solar Capital arm, because not only are we funding solar projects, but we can also fund back-up batteries, natural gas, anything within the renewables space,” Ralston said in the interview.

Direct Solar of America, a subsidiary of SinglePoint, has added Direct Solar Capital as an alternative-energy financial solution that’s able to finance capital-ready solar projects in amounts ranging from $50,000 to $3 million.

On MoneyTV, Ralston also discussed the company’s focus on its CBD business. SinglePoint is expanding its product line and has introduced new products, including a lotion product from TorusMed, he said. TorusMed has been one of the company’s strongest sellers, and its exposure has been expanded to chiropractic clinics, massage therapists and similar outlets.

Ralston noted that he is also excited about the company’s new unflavored, water-soluble tincture product that can be added to any type of beverage. It can also be rubbed right onto the skin, because it is not oily, Ralston noted.

Ralston also discussed SING’s status as a master distributor for the Pure Hemp line of American-grown hemp cigarettes. SING has already attended three trade shows as part of its due diligence process, scouting out demand for the product. Ralston said that he believes there is great opportunity in the hemp cigarette space (http://ibn.fm/c2yYo).

“Not long ago, SinglePoint made a significant commitment to be a major provider in the industrial hemp space,” Ralston observed. “And the agreement with Pure Products is another bold move for the company to solidify our place in the industry.”

For more information, visit the company’s website at www.SinglePoint.com

NOTE TO INVESTORS: The latest news and updates relating to SING are available in the company’s newsroom at http://ibn.fm/SING

• Lexaria recently announced its entry into a partnership with a tobacco giant to fund the research and development of oral nicotine delivery solutions
• The company received a cannabis R&D license from Health Canada
• LXRP also announced its receipt of four new patents and its launch of ChrgD+

Many consumers don’t realize that they don’t need to smoke to partake of nicotine. In fact, new advancements are providing an alternative to the risks associated with smoking, which were first officially revealed by a damning surgeon general report in 1963 linking smoking to lung cancer, emphysema and heart disease. Case in point, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed technology that offers an alternative method of nicotine ingestion that is safer than smoking, and the company hopes to change the world for the better by eliminating the diseases caused by combusting tobacco.

The technology, known as DehydraTECH, is a patented, cost-effective delivery mechanism that has been shown to improve the ingestibility of cannabinoids, vitamins, nonsteroid anti-inflammatory drugs (NSAIDs) and nicotine. Now, Lexaria has partnered with one of the world’s largest tobacco firms to develop new, reduced-risk, oral nicotine products using the technology (http://ibn.fm/pddAe).

The deal funds Lexaria’s R&D program – and consumer product development – in exchange for certain DehydraTECH license rights and a minority equity interest in Lexaria Nicotine, a wholly owned subsidiary of Lexaria Bioscience Corp. An initial tranche of $1 million has been provided, with additional phases providing up to $12 million total. Lexaria has granted a license for its technology to be used in nicotine-based oral-format products on an exclusive basis in the United States and a nonexclusive basis elsewhere globally, for which it will receive royalties on every dollar of revenue generated utilizing its technology.

The strength of the relationship is evident from the recent appointment of Brian Quigley to the Lexaria board of directors. Most recently, Quigley spent 16 years at the tobacco giant, with seven of those years as president and CEO of a major business unit. He is a 20-year veteran of the consumer packaged-goods industry and has managed complex regulatory environments, including those for nicotine products (http://ibn.fm/j4mMb).

Lexaria also recently announced that it had been issued a cannabis R&D license by Health Canada, with a four-year term extending to August 9, 2023 (http://ibn.fm/2IzvQ). The new license will allow one of the country’s newest and most-advanced laboratories to conduct extensive investigatory work in both THC and CBD delivery using proprietary, optimized formulations and techniques. The laboratory was purpose built, is permitted at local and federal levels, and is fully outfitted with equipment required to produce DehydraTECH infusions, including two different methodologies of creating nano-sized molecules.

The Health Canada license came at an opportune time. Lexaria recently announced the receipt of four new patents (http://ibn.fm/spv68), bringing the company’s issued patent total to 15 (eight in the United States and seven in Australia), with roughly 60 patent applications still pending throughout the world. The granted patents cover delivery of cannabinoids such as THC and CBD; NSAIDs such as ibuprofen; nicotine; and a range of vitamins.

The DehydraTECH technology has already been deployed with the launch of ChrgD+, a water-soluble, ready-mix hemp supplement powder that can be added to a variety of beverages, hot or cold (http://ibn.fm/nQKUS). At just two grams per pouch, ChrgD+ packets can be carried discreetly in a shirt pocket or purse and consumed anywhere in a soft drink, coffee or other beverage. ChrgD+ is nearly flavorless and odorless and offers minimal impact to taste; users experience a delightful food-grade pearlescent sparkle effect to remind them that they are getting its benefits.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• Lexaria Bioscience is involved in the research and improvement of its trademarked DehydraTECH technology, which enhances the bioavailability of some legal drug substances used by consumers
• The technology provides a rapid-on, rapid-off effect that may be effectively used in cannabis-infused edibles and beverages as an alternative to mind-altering substances such as alcohol and cannabis
• New research has boosted Lexaria’s hopes, with findings that show no adverse NME chemical compositions were formed in several rounds of in-depth testing
• The company recently formed a collaboration with Hill Street Beverage Company to make cannabis-infused alternatives to alcoholic beverages
• By 2024, cannabis-infused beverage sales are expected to reach $1.4 billion

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has announced the completion of a research agreement that is moving the company forward as it investigates market opportunities that would use Lexaria’s patented DehydraTECH technology to aid biological absorption of substances such as cannabinoids, nicotine and ibuprofen.

Under a master collaborative research agreement with the National Research Council of Canada (NRC), Lexaria focused on technical aspects of DehydraTECH’s drug delivery processes for speeding up lipophilic active ingredient compositions’ bioavailability to see if the technology caused the formation of a new molecular entity (NME) during activation, according to a company news release (http://ibn.fm/R94q9).

The creation of an NME would likely have burdened Lexaria’s research program with additional testing and regulation to establish the NME’s safety for human consumption under the oversight of the U.S. Food and Drug Administration (FDA) and Health Canada.

“The company is very pleased to report that all evidence aligns that no covalent-bonded NME is created with Lexaria’s technology,” the news release states.

The collaboration with the NRC analyzed 33 formulations using DehydraTECH technology out of more than 50 that were prepared. In addition to the drug substances analyzed in-depth, the research tested long chain fatty acid and medium chain triglyceride oils alone and in combination.

The testing demonstrated no shift in the spectral positioning of the API pharmaceuticals’ molecular construction for all formulations tested, which provided nearly incontrovertible evidence of a lack of any covalent-bonded NME, according to the company.

Lexaria also noted that the National Research Council of Canada study discovered the remarkable stability of DehydraTECH technology, even under highly acidic conditions. “Other formulation technologies by third parties that have not been tested for pH stability cannot be relied upon to deliver stable quantities of the API in question within an acidic beverage,” the news release states. “Since mildly acidic formulas are used in the vast majority of beverages sold in North America today, pH stability testing is a necessary aspect of safely delivering cannabinoids within popular beverage formats and Lexaria’s technology is now proven capable of doing so.”

Lexaria, through its working relationship with the NRC, continues to pursue other objectives, such as determining what interactions take place at the molecular level between nicotine polacrilex formulations and DehydraTECH’s methodology in order to continually improve on DehydraTECH and expand scientific understanding of its processes.

Lexaria announced July 24 that it will collaborate with alcohol-free and cannabis-infused beer and wine maker Hill Street Beverage Company Inc. (TSX.V: BEER) in creating a new brand of tetrahydrocannabinol (THC) and/or cannabidiol (CBD)-infused products as edible and beverage consumption of cannabis becomes nationally legal in Canada later this year (http://ibn.fm/cznv3).

Market analysts at Zenith Global forecast that the U.S. market for cannabis- and hemp-infused drinks will rocket to over $1.4 billion by 2024, reflecting a growing interest in alternatives to alcoholic beverages with a potential wellness aspect to them. Lexaria’s technology is also attractive because it provides a relatively rapid-on, rapid-off effect that reduces or eliminates the potential hazards of alcohol that carry over into other daily activities (http://ibn.fm/Acaxn).

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• MCOA’s virtual launch party introduced VivaBuds, a premium cannabis delivery service that will initially deliver to the San Fernando Valley in Los Angeles County
• Attendees were treated to a live tour of the VivaBuds website, VivaBuds swag giveaways and an invitation to become one of VivaBuds’ first customers
• VivaBuds offers the option for customers to become ‘BlazeMasters’ and build their own personal cannabis businesses by utilizing a ‘call your friend’ approach
• MCOA’s joint venture subsidiary, Covered Bridge Acres Ltd., produced a first harvest from its hemp farm in Scio, Oregon, that generated revenues of $525,000

Marijuana Company of America Inc. (OTCQB: MCOA), an innovative hemp and cannabis corporation, provided a curious public with an inside look at its new joint venture, VivaBuds, during a virtual launch party earlier this month. Customers eager to learn more about VivaBuds, a unique cannabis delivery service slated to initially begin deliveries in the San Fernando Valley of Los Angeles County, were treated to swag giveaways and details on how to become one of VivaBuds’ first retail customers.

“VivaBuds will offer our customers low-cost premium cannabis, fast delivery times, and quality customer service,” Don Steinberg, CEO of MCOA, stated in a news release prior to the launch party (http://ibn.fm/HQ4aG). “California’s cannabis delivery regulations, which were implemented earlier this year, introduced a new burgeoning market that VivaBuds will not only benefit from, but also help set the industry standard by contributing to California’s cannabis revenue surge.”

Steinberg announced in April that MCOA had acquired a 20 percent ownership interest in Natural Plant Extract of California (“NPE”), a licensed manufacturer, distributor and retail delivery service for volatile cannabis products in California (http://ibn.fm/mpOdt). The deal established a joint venture to create VivaBuds, which serves as the marketing arm for a new retail cannabis delivery service, launched earlier by NPE subsidiary Northern Lights Distribution in California.

The VivaBuds rollout remains in full swing, with the VivaBuds mobile application live on Google Play and available for download on all Android devices (http://ibn.fm/P9YMz). Customers using the app can also learn more about customizing their own buying experiences, how to enjoy premium cannabis products at wholesale pricing and how to become a ‘BlazeMaster’ and earn a commission on a referral basis.

MCOA recently reported that its joint venture subsidiary, Covered Bridge Acres Ltd. (“CBA”), has started generating revenue through operations at its hemp farm in Scio, Oregon. Through a combination of the sales of raw biomass, plantlets, CBD crude oil and CBD distillate produced from various processing test runs along with other farm operations, CBA generated $525,500 in its first year of operation (http://ibn.fm/NjZiq).

For more information, visit the company’s websites at www.MarijuanaCompanyofAmerica.com, www.VivaBuds.com and www.hempSMART.com

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• Organigram’s Q3 results marked its fourth quarter in a row of positive adjusted EBITDA*
• A Bloomberg article states that the company is an outlier due to its high margins and low production costs

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) stands out from other Canadian cannabis companies due to the fact that it has registered four quarters of positive adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), as a Bloomberg article about the enterprise reads (http://ibn.fm/BUMhB). Adjusted EBITDA is a non-IFRS measure. For more information, see the company’s latest MD&A.

Organigram’s Q3 and fiscal year-to-date results represent some of the strongest operating and financial metrics amongst Canadian licensed producers. With one of the lowest cultivation costs per gram and continued discipline on selling, general and administrative expenses, Organigram’s results place it in the top tier of the Canadian industry.

As per the Bloomberg article, Organigram’s sustainable profitability is an outlier due to the fact that the industry has been experiencing some negative developments. Regulatory measures have been undertaken in Canada against some of the cultivators to ensure compliance. Other firms have been registering lower than expected sales, significant negative adjusted EBITDA and shrinking margins in recent quarters.

Recently, Organigram announced that it has received Health Canada approval for the licensing of its phase 4A, for total licensed production capacity of 61,000 kilograms annually (http://ibn.fm/Hgp0a). The entire phase 4 expansion is expected to be completed by the end of 2019 and aims to increase target production capacity to 113,000 kg/year, once licensed and fully operational.

* Cultivation cost per gram is a non-IFRS measure. Please see the Company’s latest MD&A.

For more information, visit the company’s website at www.Investors.Organigram.ca

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://ibn.fm/OGRMF

• The Supreme Cannabis Company Inc. is Canada’s only coast-to-coast premium cannabis producer
• Supreme’s wholly owned subsidiary produces sustainably scaled, high-quality cannabis yields
• The company has entered into a definitive agreement to acquire Truverra Inc.

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) works with an eye to providing the world’s best cannabis products and emerging as a top competitor in the cannabis marketplace. As Canada’s only coast-to-coast premium cannabis producer, Supreme is engaged in widespread distribution and has an expert team of passionate professionals and employees. Furthermore, Supreme Cannabis secured a place among the highest revenue-recording, publicly traded cannabis companies in Canada with reported revenues of C$8.85 million for its fiscal year ended June 30, 2018.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

One of the company’s strengths lies in its wholly owned subsidiary, 7ACRES. With the end to 100 years of cannabis prohibition, the Canadian market is set to flourish and expand, and 7ACRES is ideally positioned to make the most of this opportunity. Situated in a 440,000-square-foot cultivation facility in Kincardine, Ontario, 7ACRES operates by the motto of ‘Craft quality, commercial scale’. One of the first 40 federally licensed cannabis producers in Canada, 7ACRES concentrates on producing sustainably scaled, premium-quality products. The fact that six Canadian provinces have signed an agreement with Supreme is a testament to 7ACRES’ exemplary quality cannabis.

In addition, on July 17, 2019, Supreme announced a definitive agreement with the privately held Truverra Inc. The deal involves the transaction of 14.7 million common shares of Supreme Cannabis, with an approximate value of $20,000,000 (http://ibn.fm/R9yCt). “The recent introduction of Health Canada’s amended cannabis regulations creates a distinct opportunity for Supreme Cannabis to establish a leading position in the cannabis extracts markets,” Dhaliwal added. “With the acquisition of Truverra, we secure a Toronto-based facility equipped to extract our high-quality inputs for concentrates and vaping liquids in the near-term.”

With the completion of this deal, Supreme will further strengthen its position in the global cannabis market. Truverra sells a wide range of CBD products (http://ibn.fm/3Y4cw) to international markets through its subsidiaries, Truverra (Europe) B. V. and Canadian Clinical Cannabinoids Inc. (“CCC”). CCC’s 5,000-square-foot licensed facility in Ontario is focused on producing cannabis derivative extracts for Legalization 2.0, or the second round of regulations in Canada, which are scheduled to commence around fall 2019.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• The immunology company released its financial results for the second quarter of 2019 and also delivered an update on its clinical trials
• The phase I trial of INmune Bio’s cancer treatment INB03 has delivered promising results in terms of safety and tolerability. The company will now be moving forward with the phase II of the trial
• INmune Bio also announced the appointment of biotechnology executive Edgardo Baracchini as a new member of the board of directors

INmune Bio Inc.’s (NASDAQ: INMB) clinical program continues to advance, CEO RJ Tesi, M.D., noted during a presentation of the company’s 2019 second quarterly report. The business update, year-to-date, focused on financial results and on the advancement of the INB03 program (http://ibn.fm/shHin).

At the beginning of August, INmune Bio announced positive preliminary data from the INB03 phase I clinical trial. INB03 is a second-generation soluble tumor necrosis factor (sTNF) inhibitor, which the company believes alters the immunobiology of the tumor microenvironment to improve tumor killing in the body.

The phase I trial enlisted patients with advanced solid tumors. These volunteers received INB03 to determine the safety of the treatment in cancer patients. The medication was administered for an average of 74 days, and no adverse side effects were reported. INB03 was well tolerated.

As the company begins phase II testing, it hopes to establish the effectiveness of the medication in combination immunotherapy.

INmune Bio also announced that it expects to begin enlisting patients for a phase I trial of its other drug candidate, XPro1595, targeting Alzheimer’s disease. Patient enrollment is expected to begin in the second half of 2019.

Apart from announcing strategic developments, INmune Bio also presented its most important financial results for the second quarter. Net loss attributable to common stockholders for the second quarter was $0.4 million, in comparison to $6.2 million for the same quarter of 2018. Research and development expenditure remained unchanged at $0.3 million. The total research and development expenditure was $0.6 million, but it was partially offset by a $0.3 million Alzheimer’s Association grant.

As of June 30, INmune Bio had cash and cash equivalents of $9.4 million with no debt. In May 2019, INmune closed a private placement of nearly $4.7 million. As of August 9, INmune Bio has 10.8 million common and 13.9 million fully diluted shares outstanding.

INmune Bio has made another important announcement in line with its strategic development plans. On August 8, 2019, the company announced that Edgardo Baracchini, Ph.D., will be joining the INmune Bio team as a member of the board of directors (http://ibn.fm/zPl7l).

Barracchini brings extensive business development and deal-making experience to the board of directors, Tesi said. These are critical skills that are expected to benefit INmune Bio as it continues to advance its three main drug candidates through clinical trials, Tesi concluded.

Baracchini has over 25 years of experience in biotech business development. He has negotiated over 80 business transactions with multinational pharmaceutical firms, biotech businesses and prominent universities. His efforts have resulted in transactions estimated at over $5.3 billion.

“INmune Bio has very exciting clinical trials in cancer and Alzheimer’s disease,” Baracchini noted in a news release. “I am looking forward to working closely with its seasoned leadership team, each of whom have demonstrated their own track record of success.”

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB